Fagron announces the acquisition of UCP in North America and FDA inspection update

About this update from Fagron Sa

[{"type":"image","alt":"Fagron NV","displaySize":"","headline":null,"caption":"Fagron NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/01507f83c8cd7cebb0a99a82c723a556"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TBfMLlZobaCODCfSBVX7eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/01507f83c8cd7cebb0a99a82c723a556","width":300,"height":108}},"lazy":false},{"type":"text","content":"Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET","length":122,"tagName":"p"},{"type":"text","content":"Fagron announces the acquisition of UCP in North America and FDA inspection update ","length":82,"tagName":"p"},{"type":"text","content":"Fagron, the leading global player in pharmaceutical compounding, is pleased to announce a strategic acquisition that will significantly reinforce its presence in North America. The company has signed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder specializing in the health and wellness segment in California, whilst adhering to a disciplined acquisition strategy.","length":408,"tagName":"p"},{"type":"text","content":"The company has also been inspected by the FDA at its Wichita and Las Vegas facilities, with none of the observations from the 2024 inspection in Wichita being now repeated, which validates our remediation has addressed the Agency’s prior concerns.","length":248,"tagName":"p"},{"type":"text","content":"UCP","length":3,"tagName":"p"},{"type":"text","content":"UCP, based in San Diego, the U.S., is a 503A pharmaceutical compounder specializing in the health and wellness segment, with strong positions in hormones and urology and a solid compliance record, making it highly complementary to Anazao and enabling a differential coast-to-coast offering. This underpins Fagron’s strategy to build a nationwide compounding platform in the U.S., spanning both 503A (patient-specific) and 503B (outsourcing) services.","length":450,"tagName":"p"},{"type":"text","content":"The acquisition deepens Fagron’s presence in North America’s prevention and lifestyle segment and strengthens our position in California, one of the largest and most tightly regulated healthcare markets in the U.S....

More updates from Fagron Sa